Skip to main content
Fuan Pharmaceutical （Group）co.,Ltd logo

Fuan Pharmaceutical （Group）co.,Ltd — Investor Relations & Filings

Ticker · 300194 ISIN · CNE1000011G4 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,014 across all filing types
Latest filing 2020-03-27 AGM Information
Country CN China
Listing Shenzhen Stock Exchange 300194

About Fuan Pharmaceutical （Group）co.,Ltd

https://www.fapharm.com

Fuan Pharmaceutical (Group) Co., Ltd. is an integrated pharmaceutical enterprise specializing in the research, development, production, and distribution of a wide range of chemical drugs. The company operates across the entire value chain, encompassing pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage forms. Its product portfolio primarily focuses on anti-infectives, particularly cephalosporins and penicillins, as well as treatments for cardiovascular diseases, oncology, and respiratory conditions. Fuan Pharmaceutical maintains large-scale manufacturing facilities and emphasizes technological innovation to support its diverse pipeline of generic and specialized medications. The group serves both domestic and international markets, providing essential healthcare solutions through its network of subsidiaries and specialized production bases.

Recent filings

Filing Released Lang Actions
关于召开2019年年度股东大会的通知
AGM Information Classification · 95% confidence The document is a notice about the convening of the 2019 Annual General Meeting (AGM) of 福安药业 (Fuan Pharmaceutical Group Co., Ltd.). It includes details about the meeting date, voting procedures, agenda items to be discussed (such as the 2019 annual report, audit report, financial statements, profit distribution plan, and reappointment of auditors), and instructions for shareholders to participate either in person or via online voting. The document does not contain the actual annual report, financial statements, or audit report, but rather announces the meeting where these reports will be reviewed and voted upon. The document length is 4790 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting, including notices and agendas.
2020-03-27 Chinese
独立董事2019年度述职报告（熊文说）
Management Reports Classification · 95% confidence The document is titled as an "Independent Director's Annual Report" for the year 2019 by an independent director of the company. It details the director's attendance at board and shareholder meetings, opinions on various company matters, committee work, investigations, and efforts to protect investor rights during the year. The content is a narrative report on the independent director's duties and activities rather than a full financial report or audit. It does not contain financial statements or detailed financial data. This type of document is a management or director report on their activities and opinions, which fits best under the category of Management Reports (MDA). The document length is 2040 characters, which is relatively short but contains substantive content about management oversight rather than just an announcement or certification. Therefore, the classification is MDA with high confidence.
2020-03-27 Chinese
2019年年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled as an audit report for the fiscal year 2019 of 福安药业（集团）股份有限公司. It contains detailed financial statements including consolidated and parent company balance sheets, income statements, cash flow statements, and notes. The text includes an auditor's opinion, basis for the opinion, key audit matters, and responsibilities of management and auditors. The presence of detailed financial data and the auditor's report indicates this is a standalone audit report rather than a full annual report or other filing. The document length is substantial (15,000 characters), and it is not merely an announcement or certification. Therefore, the document fits the definition of an Audit Report / Information (AR). FY 2019
2020-03-27 Chinese
关于会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from 福安药业（集团）股份有限公司 regarding a change in accounting policy. It details the reasons for the change, the previous and new accounting policies, the date of change, and the approval process by the board and supervisory committee. The document does not contain financial statements or detailed financial data but rather informs stakeholders about the policy change and related approvals. It is a regulatory announcement about accounting policy changes rather than a full financial report or audit report. Given the content and length (1929 characters), it fits best as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-03-27 Chinese
2019年度控股股东及其他关联方占用资金情况专项审核报告
Audit Report / Information Classification · 95% confidence The document is titled as a "专项审核报告" (special audit report) concerning the 2019 year-end situation of funds occupied by controlling shareholders and other related parties of 福安药业(集团)股份有限公司. It is issued by an accounting firm (永拓会计师事务所) and references auditing standards and the company's audited financial statements for 2019. The document includes a summary table of fund occupation and is intended for regulatory disclosure regarding related party transactions. It is not a full annual report (10-K), nor a general audit report of the entire financial statements, but a specialized audit report focusing on related party fund occupation. This fits the definition of an Audit Report / Information (AR) as it is a standalone audit report on a specific issue, separate from the full annual report. The document length is 2241 characters, which is short but contains substantive audit content, not merely an announcement or certification. Therefore, the classification is AR with high confidence. FY 2019
2020-03-27 Chinese
2019年度监事会工作报告
Management Reports Classification · 95% confidence The document is titled '2019 年度监事会工作报告' which translates to '2019 Supervisory Board Work Report'. It details the supervisory board's activities, meetings, and oversight of the company's operations, financials, internal controls, and compliance during the 2019 fiscal year. It includes summaries of meetings where financial reports, audit reports, and internal control evaluations were reviewed and approved. The document is a report from the supervisory board on their work and oversight, not the full annual report or audit report itself. It is a management-related report focusing on governance and supervisory activities rather than a financial statement or audit opinion standalone. Therefore, it fits best under the category of Management Reports (MDA), which covers management's detailed explanation of financial results, business trends, and outlook, including supervisory board reports on company operations and compliance.
2020-03-27 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.